Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Илопрост – доступный простациклин для терапии легочной артериальной гипертензии
Илопрост – доступный простациклин для терапии легочной артериальной гипертензии
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Морман Д., Хеллер Л. Физиология сердечно-сосудистой системы. СПб.: Питер, 2000.
2. Fetalvero KM, Martin KA, Hwa J. Cardioprotective prostacyclin signaling in vascular smooth musle. Prostaglandins Other Lipid Mediators 2007; 82: 109–18.
3. Мари Р., Гренер Д., Мейес П. Метаболизм ненасыщенных жирных кислот и эйказаноидов. М.: Мир, 1993.
4. Ольбинская Л.И., Литвицкий П.Ф. Коронарная и миокардиальная недостаточность. М.: Медицина, 1986.
5. Moncada S, Vane J. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmac Rev 1979; 30: 292–305.
6. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Современные подходы к лечению пациентов с легочной гипертензией в свете рекомендаций Европейского Общества кардиологов. Cons. med. 2005;7 (11): 957–62.
7. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9.
8. Olschewski H, Hoeper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010; 104: 731–40.
9. Guo XX, Tian Z, Liu YT et al. Effects of inhaled aerosolized iloprost in adult patients with pulmonary arterial hypertension on right heart functions. Zhonghua Yi Xue Za Zhi 2011; 40 (91): 2832–6.
10. Gabrielli LA, Castro PF, Godoy I et al. Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients. J Card Fail 2011; 12 (17): 1012–7.
11. Birukova AA, Wu T, Tian Y et al. Iloprost improves endothelial barrier function in LPS-induced lung injury. Eur Respir J 2012; PMID: 22790920.
12. John J, Palevsky H. Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. Expert Rev Clin Pharmacol 2011; 2 (4): 197–205.
13. Kirbas A, Yalcin Y, Tanrikulu N et al. Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery. J Cardiol 2012; 4 (19): 387–94.
14. Gokce I, Kahveci H, Turkyilmaz Z et al. Inhaled iloprost in the treatment of pulmonary hypertension in very low birth weight infants: a report of two cases. J Pak Med Assoc 2012; 4 (62): 388–91.
15. Yang SI, Chung WJ, Jung SH, Choi DY. Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome. Pediatr Cardiol 2012; 5 (33): 744–8.
16. Keith RL, Blatchford PJ, Kittelson J et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 2011; 6 (4): 793–802.
17. Darcin OT, Zor MH, Sahin V et al. Effect of Iloprost on renal function in patients undergoing coronary artery bypass grafting: a clinical study. Ann Thorac Cardiovasc Surg 2012; PMID: 22785552.
18. Ege T, Gur O, Karadag CH, Duran E. Evaluation of iloprost to prevent vasospasm in coronary artery bypass grafts. J Int Med Res 2010; 5 (38): 1759–63.
19. Canacankatan N, Sucu N, Aytacoglu B et al. Affirmative effects of iloprost on apoptosis during ischemia-reperfusion injury in kidney as a distant organ. Ren Fail 2012; 1 (34): 111–8.
20. Brodszky V, Farkas K, Járai Z et al. Effectiveness of prostanoids in patients with critical leg ischemia. Orv Hetil 2011; 152 (51): 2047–55.
21. Blardi P, de Lalla A, Pieragalli D et al. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease. Prostaglandins Other Lipid Mediat 2006; 80 (3–4): 175–82.
22. Piaggesi A, Vallini V, Iacopi E et al. Iloprost in the management of peripheral arterial disease in patients with diabetes mellitus. Minerva Cardioangiol 2011; 1 (59): 101–18.
23. Yeh CH, Kuo CH, Yang SN et al. Prostaglandin I2 analogs suppress tumor necrosis factor a production and the maturation of human monocyte-derived dendritic cells. J Investig Med 2011; 7 (59): 1109–15.
24. Karatepe O, Cakir A, Unal O et al. Iloprost reduces colonic injury in ischemic colitis in rats. Acta Cir Bras 2011; 3 (26): 220–6.
25. Muzaffar S, Shukla N, Massey Y et al. NADPH oxidase 1 mediates upregulation of thromboxane A2 synthase in human vascular smooth muscle cells: inhibition with iloprost. Eur J Pharmacol 2011; 658 (2–3): 187–92.
2. Fetalvero KM, Martin KA, Hwa J. Cardioprotective prostacyclin signaling in vascular smooth musle. Prostaglandins Other Lipid Mediators 2007; 82: 109–18.
3. Мари Р., Гренер Д., Мейес П. Метаболизм ненасыщенных жирных кислот и эйказаноидов. М.: Мир, 1993.
4. Ольбинская Л.И., Литвицкий П.Ф. Коронарная и миокардиальная недостаточность. М.: Медицина, 1986.
5. Moncada S, Vane J. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmac Rev 1979; 30: 292–305.
6. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Современные подходы к лечению пациентов с легочной гипертензией в свете рекомендаций Европейского Общества кардиологов. Cons. med. 2005;7 (11): 957–62.
7. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9.
8. Olschewski H, Hoeper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010; 104: 731–40.
9. Guo XX, Tian Z, Liu YT et al. Effects of inhaled aerosolized iloprost in adult patients with pulmonary arterial hypertension on right heart functions. Zhonghua Yi Xue Za Zhi 2011; 40 (91): 2832–6.
10. Gabrielli LA, Castro PF, Godoy I et al. Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients. J Card Fail 2011; 12 (17): 1012–7.
11. Birukova AA, Wu T, Tian Y et al. Iloprost improves endothelial barrier function in LPS-induced lung injury. Eur Respir J 2012; PMID: 22790920.
12. John J, Palevsky H. Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. Expert Rev Clin Pharmacol 2011; 2 (4): 197–205.
13. Kirbas A, Yalcin Y, Tanrikulu N et al. Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery. J Cardiol 2012; 4 (19): 387–94.
14. Gokce I, Kahveci H, Turkyilmaz Z et al. Inhaled iloprost in the treatment of pulmonary hypertension in very low birth weight infants: a report of two cases. J Pak Med Assoc 2012; 4 (62): 388–91.
15. Yang SI, Chung WJ, Jung SH, Choi DY. Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome. Pediatr Cardiol 2012; 5 (33): 744–8.
16. Keith RL, Blatchford PJ, Kittelson J et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 2011; 6 (4): 793–802.
17. Darcin OT, Zor MH, Sahin V et al. Effect of Iloprost on renal function in patients undergoing coronary artery bypass grafting: a clinical study. Ann Thorac Cardiovasc Surg 2012; PMID: 22785552.
18. Ege T, Gur O, Karadag CH, Duran E. Evaluation of iloprost to prevent vasospasm in coronary artery bypass grafts. J Int Med Res 2010; 5 (38): 1759–63.
19. Canacankatan N, Sucu N, Aytacoglu B et al. Affirmative effects of iloprost on apoptosis during ischemia-reperfusion injury in kidney as a distant organ. Ren Fail 2012; 1 (34): 111–8.
20. Brodszky V, Farkas K, Járai Z et al. Effectiveness of prostanoids in patients with critical leg ischemia. Orv Hetil 2011; 152 (51): 2047–55.
21. Blardi P, de Lalla A, Pieragalli D et al. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease. Prostaglandins Other Lipid Mediat 2006; 80 (3–4): 175–82.
22. Piaggesi A, Vallini V, Iacopi E et al. Iloprost in the management of peripheral arterial disease in patients with diabetes mellitus. Minerva Cardioangiol 2011; 1 (59): 101–18.
23. Yeh CH, Kuo CH, Yang SN et al. Prostaglandin I2 analogs suppress tumor necrosis factor a production and the maturation of human monocyte-derived dendritic cells. J Investig Med 2011; 7 (59): 1109–15.
24. Karatepe O, Cakir A, Unal O et al. Iloprost reduces colonic injury in ischemic colitis in rats. Acta Cir Bras 2011; 3 (26): 220–6.
25. Muzaffar S, Shukla N, Massey Y et al. NADPH oxidase 1 mediates upregulation of thromboxane A2 synthase in human vascular smooth muscle cells: inhibition with iloprost. Eur J Pharmacol 2011; 658 (2–3): 187–92.
Авторы
А.И.Инжутова
ГБОУ ВПО Красноярский государственный медицинский университет им. проф. В.Ф.Войно-Ясенецкого
ГБОУ ВПО Красноярский государственный медицинский университет им. проф. В.Ф.Войно-Ясенецкого
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.